Opus Capital Group LLC Has $287,000 Position in AstraZeneca plc (NYSE:AZN)

Opus Capital Group LLC decreased its holdings in AstraZeneca plc (NYSE:AZN) by 7.1% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,105 shares of the company’s stock after selling 545 shares during the quarter. Opus Capital Group LLC’s holdings in AstraZeneca were worth $287,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also made changes to their positions in AZN. Lake Point Wealth Management bought a new stake in shares of AstraZeneca during the 4th quarter valued at about $195,000. Mackenzie Financial Corp lifted its position in shares of AstraZeneca by 311.8% during the 4th quarter. Mackenzie Financial Corp now owns 122,231 shares of the company’s stock valued at $4,642,000 after buying an additional 92,551 shares in the last quarter. Pinkerton Retirement Specialists LLC lifted its position in shares of AstraZeneca by 0.8% during the 4th quarter. Pinkerton Retirement Specialists LLC now owns 66,695 shares of the company’s stock valued at $2,533,000 after buying an additional 536 shares in the last quarter. Sit Investment Associates Inc. purchased a new position in shares of AstraZeneca during the 4th quarter valued at about $171,000. Finally, Wealth Alliance Advisory Group LLC purchased a new position in shares of AstraZeneca during the 4th quarter valued at about $216,000. 18.65% of the stock is owned by institutional investors.

A number of research firms recently commented on AZN. HSBC reissued a “sell” rating on shares of AstraZeneca in a report on Thursday, February 28th. ValuEngine cut AstraZeneca from a “buy” rating to a “hold” rating in a report on Monday, April 1st. BNP Paribas began coverage on AstraZeneca in a report on Tuesday, February 5th. They issued an “outperform” rating on the stock. UBS Group cut AstraZeneca from a “neutral” rating to a “sell” rating and set a $40.73 price target on the stock. in a report on Tuesday, April 2nd. Finally, Exane BNP Paribas began coverage on AstraZeneca in a report on Tuesday, February 5th. They issued an “outperform” rating on the stock. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and twelve have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $45.29.

Shares of NYSE AZN traded up $0.36 during trading hours on Friday, hitting $39.02. 2,975,803 shares of the company traded hands, compared to its average volume of 5,362,723. The company has a market cap of $98.91 billion, a P/E ratio of 11.28, a P/E/G ratio of 1.17 and a beta of 0.47. The company has a debt-to-equity ratio of 1.48, a quick ratio of 0.58 and a current ratio of 0.75. AstraZeneca plc has a 12 month low of $34.38 and a 12 month high of $43.29.

AstraZeneca (NYSE:AZN) last released its earnings results on Friday, April 26th. The company reported $0.45 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.43 by $0.02. The firm had revenue of $5.47 billion for the quarter, compared to the consensus estimate of $5.40 billion. AstraZeneca had a return on equity of 37.91% and a net margin of 10.75%. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.48 EPS. As a group, equities analysts predict that AstraZeneca plc will post 1.79 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This story was reported by Sundance Herald and is the sole property of of Sundance Herald. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://sundanceherald.com/2019/05/24/astrazeneca-plc-azn-shares-sold-by-opus-capital-group-llc.html.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

See Also: How is inflation measured?

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply